LURTOTECAN DIHYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H30N4O6.2ClH
Molecular Weight	591.483
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.Cl.CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C3N=C5C=C6OCCOC6=CC5=C4CN7CCN(C)CC7)C2=O

InChI

InChIKey=ORIWMYRMOGIXGG-ZXVJYWQYSA-N

InChI=1S/C28H30N4O6.2ClH/c1-3-28(35)20-11-22-25-18(14-32(22)26(33)19(20)15-38-27(28)34)17(13-31-6-4-30(2)5-7-31)16-10-23-24(12-21(16)29-25)37-9-8-36-23;;/h10-12,35H,3-9,13-15H2,1-2H3;2*1H/t28-;;/m0../s1

HIDE SMILES / InChI

Molecular Formula	C28H30N4O6
Molecular Weight	518.561
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://adisinsight.springer.com/drugs/800004939 | https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lurtotecan

Lurtotecan is a semisynthetic analog of camptothecin with antineoplastic activity. It is an inhibitor of DNA topoisomerase I. Liposomal formulation of lurtotecan was being studied in the treatment of cancer. Lurtotecan development has been discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA topoisomerase I 59 Target ID: CHEMBL1781 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9632354 \| https://www.ncbi.nlm.nih.gov/pubmed/9328158	Inhibitor 8297

PubMed

Title	Date	PubMed
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice.	2001 Mar	11290871
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.	2002 Feb	12003197
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.	2002 Mar	11895919
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.	2002 Mar 1	11870164
[A symphony for the camptothecins].	2003 Mar	12801826
Are there any better camptothecins than the ones we have?	2003 Oct	16258452
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.	2004 Apr 1	15042679
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.	2004 Dec	15571957
Gateways to clinical trials.	2004 Jun	15319815
Gateways to clinical trials.	2005 Dec	16395422
Gateways to clinical trials.	2005 Jul-Aug	16179960
Experimental designs for phase I and phase I/II dose-finding studies.	2006 Mar 13	16434987

Patents

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:09:05 GMT 2023` Edited by `admin` on `Sat Dec 16 05:09:05 GMT 2023`
Record UNII	S31P37BX03
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LURTOTECAN DIHYDROCHLORIDE

Official Name

English

(8S)-8-ETHYL-2,3-DIHYDRO-8-HYDROXY-15-((4-METHYL-1-PIPERAZINYL)METHYL)-11H-P-DIOXINO(2,3-G)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-9,12(8H,14H)-DIONE DIHYDROCHLORIDE

Common Name

English

LURTOTECAN DIHYDROCHLORIDE [USAN]

Common Name

English

GI-147211C

Code

English

GI147211C

Code

English

11H-1,4-DIOXINO(2,3-G)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-9,12(8H,14H)-DIONE, 8-ETHYL-2,3-DIHYDRO-8-HYDROXY-15-((4-METHYL-1-PIPERAZINYL)METHYL)-, DIHYDROCHLORIDE, (S)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2843